Fatal panresistant Lomentospora prolificans fungemia in a patient with aplastic anemia: First report from Türkiye

IF 2.2 4区医学 Q3 MYCOLOGY

Journal de mycologie medicale Pub Date : 2023-08-04 DOI:10.1016/j.mycmed.2023.101416

Zeynep Yazgan , Tansu Dündar , Ayşe Barış , Özge Aksu , Ahmet Emre Eşkazan , Fatma Köksal Çakırlar

{"title":"Fatal panresistant Lomentospora prolificans fungemia in a patient with aplastic anemia: First report from Türkiye","authors":"Zeynep Yazgan , Tansu Dündar , Ayşe Barış , Özge Aksu , Ahmet Emre Eşkazan , Fatma Köksal Çakırlar","doi":"10.1016/j.mycmed.2023.101416","DOIUrl":null,"url":null,"abstract":"<div>Lomentospora prolificans is an opportunistic pathogen that can cause invasive lomentosporiosis in immunocompromised patients. Patients with hematological malignancies and those who have undergone stem cell or solid organ transplantations are in the highest risk group. In addition to the limitations and delays in diagnostic possibilities, L. prolificans has a high mortality due to its resistance to all available antifungal drugs. In a patient diagnosed with aplastic anemia, we described the first case of L. prolificans in Türkiye. L. prolificans was identified in the blood culture, and despite the initiation of antifungal treatments, the fungemia resulted in mortality on the 7th day of intensive care hospitalization. This case highlights the importance of early recognition and prompt initiation of appropriate antifungal therapy to improve the outcome of patients with rare mold infections.</div>","PeriodicalId":14824,"journal":{"name":"Journal de mycologie medicale","volume":null,"pages":null},"PeriodicalIF":2.2000,"publicationDate":"2023-08-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal de mycologie medicale","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1156523323000604","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"MYCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Lomentospora prolificans is an opportunistic pathogen that can cause invasive lomentosporiosis in immunocompromised patients. Patients with hematological malignancies and those who have undergone stem cell or solid organ transplantations are in the highest risk group. In addition to the limitations and delays in diagnostic possibilities, L. prolificans has a high mortality due to its resistance to all available antifungal drugs. In a patient diagnosed with aplastic anemia, we described the first case of L. prolificans in Türkiye. L. prolificans was identified in the blood culture, and despite the initiation of antifungal treatments, the fungemia resulted in mortality on the 7th day of intensive care hospitalization. This case highlights the importance of early recognition and prompt initiation of appropriate antifungal therapy to improve the outcome of patients with rare mold infections.

查看原文本刊更多论文

再生障碍性贫血患者致死性泛耐药增殖性骆菌菌血症:来自 rkiye的首次报告

多发性洛美孢子虫是一种机会性病原体，可在免疫功能受损的患者中引起侵袭性洛美孢子菌病。血液系统恶性肿瘤患者和接受过干细胞或实体器官移植的患者属于高危人群。除了诊断可能性的局限性和延迟性外，由于对所有可用的抗真菌药物都有耐药性，多产乳杆菌的死亡率也很高。在一名被诊断为再生障碍性贫血的患者中，我们描述了土耳其首例多产乳杆菌病例。在血液培养中发现了多产乳杆菌，尽管开始了抗真菌治疗，但在重症监护住院的第7天，真菌血症导致了死亡。该病例强调了早期识别和及时开始适当的抗真菌治疗以改善罕见霉菌感染患者预后的重要性。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Journal de mycologie medicale 医学-真菌学

CiteScore

5.10

自引率

2.80%

发文量

审稿时长

6-12 weeks

期刊介绍： The Journal de Mycologie Medicale / Journal of Medical Mycology (JMM) publishes in English works dealing with human and animal mycology. The subjects treated are focused in particular on clinical, diagnostic, epidemiological, immunological, medical, pathological, preventive or therapeutic aspects of mycoses. Also covered are basic aspects linked primarily with morphology (electronic and photonic microscopy), physiology, biochemistry, cellular and molecular biology, immunochemistry, genetics, taxonomy or phylogeny of pathogenic or opportunistic fungi and actinomycetes in humans or animals. Studies of natural products showing inhibitory activity against pathogenic fungi cannot be considered without chemical characterization and identification of the compounds responsible for the inhibitory activity. JMM publishes (guest) editorials, original articles, reviews (and minireviews), case reports, technical notes, letters to the editor and information. Only clinical cases with real originality (new species, new clinical present action, new geographical localization, etc.), and fully documented (identification methods, results, etc.), will be considered. Under no circumstances does the journal guarantee publication before the editorial board makes its final decision. The journal is indexed in the main international databases and is accessible worldwide through the ScienceDirect and ClinicalKey platforms.